861065-72-7

Upstream product

• 83799-60-4 (4-hydroxy-3,5-dinitro-phenyl)-acetic acid ethyl ester 
• 124-63-0 methanesulfonyl chloride 
• 150-76-5 4-methoxy-phenol 
• 156-38-7 4-hydroxyphenylacetate 
• 98-59-9 p-toluenesulfonyl chloride 
• 10463-37-3 (4-hydroxy-3,5-dinitro-phenyl)-acetic acid 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 

Downstream Products

• 67-30-1 tetrac 
• 1300559-71-0 methyl {4-[4-(2-chloroethoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}-acetate 
• 1300559-73-2 Lithium [4-(4-{2-[(diaminomethylene)amino]ethoxy}-3,5-diiodophenoxy)-3,5-diiodophenyl]acetate 
• 1300559-75-4 (4-{4-[2-(carbamoylamino)ethoxy]-3,5-diiodophenoxy}-3,5-diiodophenyl)acetic acid 
• 1300559-77-6 {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid 
• 101588-11-8 C₁₇H₂₀N₂O₄ 
• 85828-82-6 [3,5-diiodo-4-(4-methoxy-phenoxy)-phenyl]-acetic acid ethyl ester 
• 1300857-63-9 C₁₈H₁₇I₄NO₄ 
• 1300559-73-2 lithium [4-(4-{2-[(diaminomethylene)amino]-ethoxy}-3,5-diiodophenoxy)-3,5-diiodophenyl]acetate 

Relevant academic research and scientific papers

Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer

In the angiogenesis process, integrins, which are members of a family of cell surface transmembrane receptors, play a critical role particularly in blood vessel formation and the local release of vascular growth factors. Thyroid hormones such as L-thyroxine (T4) and 3,5,3′-triiodo-L-thyronine (T3) promote angiogenesis and tumor cell proliferation via integrin αvβ3 receptor. At or near an arginine-glycine-aspartate (RGD) recognition site on the binding pocket of integrin αvβ3, tetraiodothyroacetic acid (tetrac, a deaminated derivative of T4) is a thyrointegrin receptor antagonist and blocks the actions of T3 and T4 as well as different growth factors-mediated angiogenesis. In this study, we synthesized novel tetrac analogs by modifying the phenolic moiety of tetrac and tested them for their anti-angiogenesis activity using a Matrigel plug model for angiogenesis in mice. Pharmacological activity results showed that tetrac can accommodate numerous modifications and maintain its anti-angiogenesis activity.

COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS

A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and alphavbeta3 integrin antagonist in the same molecule

Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: New anti-angiogenesis analogs

Context: Inhibition of pathological angiogenesis. Objective: Obtaining new transactivator, bifunctional, thyroid antagonist, non-toxic anti-angiogenic compounds. Materials and methods: In silico drug design, synthesis in bulk and biological evaluation in chick chorioallantoic membrane (CAM) model. Results: Significant inhibition (range 6573%) at 0.252.0 g/ml doses. Discussion and conclusion: The synthesis of compounds (9), (10), and (11) incorporating long-chain moieties guanidine, urea, methyl amine and, propyl amine substitutions, respectively, into the core molecular framework of tetrac (tetraiodothyroacetic acid) were undertaken. The evaluation of the anti-angiogenic bioactivity of these compounds in the CAM model revealed no loss of activity in comparison with tetrac and XT199, which showed nearly 86% inhibition at dose levels of 1 and 0.5 g/ml, respectively, and validated the concept.